A team led by IBEC with IQAC-CSIC and the University of Barcelona reports the molecule reduced the Alzheimer's-linked protein in mouse studies.
Recap by typeshit. Full story at Medical Xpress.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
An investing take on Novo Nordisk shares after a 75% drop, weighing whether the Wegovy maker is a bargain or a trap.
A clinical primer on the GIP/GLP-1 drug covering its use for blood sugar control and lowering the risk of adverse outcomes.
Loading…